Pfizer reported positive Phase 2b data for the ultra‑long‑acting GLP‑1 acquired with Metsera and said the readouts underpin a broad Phase 3 program. The company disclosed statistically significant placebo‑adjusted weight loss at 28 weeks and outlined plans for a multi‑trial pivotal program to test higher doses and combinations. Pfizer framed the data as validating monthly maintenance dosing while signaling an accelerated development timeline toward obesity indications. The results come after Pfizer paid about $10 billion for Metsera’s asset and follow an industry‑wide push toward less‑frequent GLP‑1 regimens. Pfizer executives told investors they will pursue higher dose arms in Phase 3 after seeing the Phase 2 tolerability and efficacy profile. The readout prompted a near‑term stock reaction but left investors focused on how Pfizer’s monthly candidate will compare with Lilly and Novo Nordisk’s leading products. Why it matters: Pfizer is using the Metsera asset as a cornerstone of a renewed obesity strategy; success in Phase 3 would validate a once‑monthly maintenance model and reshape patient adherence and competitive positioning across the market.